Improving outcomes in SLE [ 1/1/2021 - 12/31/2025 ]

Research Grant

Brief description There has been no significant breakthrough in the treatment of Systemic Lupus Erythematosus (SLE) for over 50 years. Treatment continues to rely on non-specific immunosuppressant drugs and glucocorticoids (GC, or ‘steroids’), and the impact on patients includes high mortality and poor quality of life. In this proposal, I will validate novel endpoints which will break the impasse in SLE drug development and develop tools for minimising GC use in SLE.

Funding Amount $1,425,000

Funding Scheme Investigator Grants

Chief Investigator Prof Eric Morand

Notes Leadership 3